Poster Abstracts • OFID 2018:5 (Suppl 1) • S513 to pharmacy-managed surveillance software for AST review and intervention. The primary outcome was time to optimal therapy (TOT) from initial culture positivity. Secondary outcomes included TOT based on organism and clinical pharmacy staffing hours, hospital length of stay, and all-cause mortality.
Background. Rapid organism identification (ID) and antimicrobial susceptibility testing (AST) are critical to treatment of infected patients. We sought to capture time between specimens collected for bacterial culture and appropriate therapy for patients, along with other pertinent patient management data from 2017 (without MALDI-TOF/Vitek 2 and ASP) and 2018 (with MALDI-TOF/Vitek 2 and ASP). Results. Mean patient age and Charlson comorbidity index was not significantly different between 2017 and 2018. Time to obtain culture, delivery to Microbiology, and Gram-stain was not different between the two groups. Time to organism ID was significantly faster in 2018 (2018, 25.2 ± 13.7; 2017, 34 .2 ± 17 hours, P = 0.001). Time to AST results was also significantly faster for patients in 2018 compared with 2017 (19.8 ± 14.1 compared with 28.5 ± 15.1 hours, P = 0.001). ASP recommended significantly more adjustments to empiric antimicrobial therapy (25% of 2018 vs. 1% in 2017, P < 0.001). In addition, length of hospital stay was significantly shorter for patients in 2018 compared with 2017 (2018, 8.3 ± 7 days; 2017, 15.6 ± 18 .3 days, P < 0.001). Finally, in-hospital length of antimicrobial therapy was significantly shorter in 2018 compared with 2017 (2018, 6.6 ± 3.7 days; 2017, 8.8 ± 7 .7 days, P < 0.05).
Conclusion. The use of MALDI-TOF/Vitek 2 leads to an average 18 hours faster microbial ID and AST results. ASP is able to make recommendations for infectious diseases management more appropriately with quicker ID and AST results.
Disclosures. Methods. In October 2016, the Xpert® MRSA/SA BC assay, a PCR to detect MRSA from blood cultures, was implemented at Kelowna General Hospital. MRSA PCR was performed on one bottle per episode for blood cultures with Gram-positive cocci in clusters in at least 3/4 bottles. The medical microbiologist promptly phoned the most responsible physician with results to streamline antibiotics. All episodes of MSSA bacteremia between January 1, 2013 to September 30, 2016 (pre-implementation group) and November 1, 2016 to January 31, 2018 (post-implementation group), were matched to corresponding vancomycin defined daily doses (DDD) and days of therapy (DOT) in pharmacy records. Patients with ≥5 DOTs were excluded if they had allergies to β-lactams, polymicrobial infections with organisms requiring vancomycin, were on hemodialysis (vancomycin convenience dosing), or were transferred from another hospital with known S. aureus bacteremia. Mean vancomycin DDDs and DOTs, and the proportion of patients receiving at least one dose of vancomycin, were compared between groups. Categorical variables were analyzed using the chi-square test, while continuous variables were compared using the t-test.
Results. In the pre-PCR group, 383 episodes of MSSA bacteremia were identified, with 21 excluded. In the post-PCR group, 100 episodes were found, with 3 excluded.
Significantly more patients received at least one dose of vancomycin in the pre-PCR (70.2%) compared with the post-PCR group (54.6%) (P < 0.01). The mean DDD was 1.5 in the post-PCR group, less than the pre-PCR group at 2.8 (P < 0.01). The mean DOT also decreased, with the post-PCR group receiving less vancomycin (1.6 days) compared with the pre-PCR group (2.5 days) (P < 0.01).
Conclusion. Rapidly available MRSA PCR for S. aureus bloodstream infection coupled with antimicrobial stewardship performed by medical microbiologists led to a significant decrease in vancomycin use.
Disclosures. 
